Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2015 08:30 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics to Participate in the ROTH Immuno-Oncology Corporate Access Day

DURHAM, N.C., Dec. 9, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
November 16, 2015 07:30 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics Reports Third Quarter 2015 Financial Results and Operational Highlights

- Completed Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 - - Established Scientific Advisory Board - - Early stage RCC trial of AGS-003 initiated at Roswell Park Cancer...
November 09, 2015 08:30 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics to Host Third Quarter 2015 Financial Results Conference Call on Monday, November 16, 2015

DURHAM, N.C., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
November 06, 2015 08:30 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics to Participate in 3rd Annual EU Advanced Therapies Investor Day

DURHAM, N.C., Nov. 6, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
November 05, 2015 08:30 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics to Participate in the 3rd International mRNA Health Conference

DURHAM, N.C., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
October 05, 2015 08:30 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics to Host Review of the Current Clinical Research Landscape in Kidney Cancer Following the 40th Congress of the European Society for Medical Oncology, With Insights From Dr. Charles Drake of Johns Hopkins Sidney Kimmel Cancer Center

DURHAM, N.C., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
October 02, 2015 08:30 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics to Participate in 2015 Stem Cell Meeting on the Mesa

DURHAM, N.C., Oct. 2, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
September 23, 2015 08:30 ET | Source: Argos Therapeutics, Inc.

Robert F. Carey Appointed to the Board of Directors of Argos Therapeutics

DURHAM, N.C., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
September 08, 2015 08:30 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics to Participate in FBR Second Annual Healthcare Conference

DURHAM, N.C., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
September 01, 2015 08:30 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics to Participate in Stem Cells and Regenerative Medicine Congress 2015

DURHAM, N.C., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...